ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia. The …
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia. The …
Breast cancer is the second most common type of cancer in women, according to the Mayo Clinic, and while survival …
CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated …
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic …
IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, …
Trial acceleration has been a topic of conversation for the pharmaceutical sector for years and as technology advances, it is …
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a …
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
According to the World Health Organization, approximately one in 127 individuals worldwide had autism spectrum disorder (ASD) in 2021. ASD …
Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact …
Kardium has unveiled further results from the pivotal trial of its Globe Pulsed Field System, demonstrating the system’s success in …
Bio Behavioral Health (BBH) has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials. The collaboration …
Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. The transaction will …
Rare disease biotech Genespire is looking to take its single-dose gene therapy – GENE202 – to the clinic in 2026, …
IntraBio will head to regulators after its neurological rare disease drug met primary and secondary endpoints in a Phase III …